NCT07695779Not yet recruitingPhase 1
A Single-Center, Double-Blind, Placebo-Controlled, Dose-Escalating Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and QT Interval Effects of Oral FXS5626 Tablets in Healthy Chinese Participants
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1 site in 1 country28 target enrollmentStarted: August 5, 2026Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Effect on QTcF between baseline and post-dose treatment of FXS5626
Study Overview
Brief Summary
The purpose of this study is to evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc interval of a single oral dose of FXS5626 in healthy subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy, adult, male or female,18-45 years of age (inclusive), with a Body Mass Index (BMI) of 19.0-28.0 kg/m2 (inclusive),have a minimum weight of at least 50kg(male) or 45kg(female).
- •Medically healthy with no clinically significant medical history, physical examination,laboratory profiles, vital signs or ECG abnormalities , as deemed by the PI or designee.
- •Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.
- •Female subjects of childbearing potential and male subjects with a partner of childbearing potential who voluntarily signed ICF should be no fertile, sperm/egg donation for 3 months from the beginning to the last dose, and voluntary use highly effective contraception (including partner) (non-drug contraception is required during the trial).
- •Exclusive Criteria:
- •Female subjects who are pregnant,or breastfeeding,or with a positive pregnancy test
- •Allergic constitutions (such as allergies to two or more drugs, foods, and pollen), or determined by the investigator, may be allergic to the investigational product or any component of the investigational product.
- •Subjects with a prior or present history of clinically abnormal metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disease who were judged by the investigator to be unsuitable for participation in this study.
- •Subjects who have a history of other risk factors for tachycardia, or a family history of a first-degree relative (i.e. biological parent, sibling, or child) of short QT syndrome, long QT syndrome, or sudden unexplained death in young age (≤40 years).
- •Significant screening ECG abnormalities,QTcF interval > 450ms (Fridericia's correction), or QRS>120ms,or PR interval >=210ms or <=120ms
- •Subjects who have got severe infections within 2 months before screening; Or have a history of active bacterial infection or viral infection or fungal infection within 2 weeks before screening
- •Subjects virus serological test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, treponema pallidum specific antibody TPPA) positive results.
- •Subjects with a history of drug abuse,or who screened positive for drug abuse.
- •Subjects who consumed more than 14 units of alcohol per week in the 6 months prior before screening (1 unit of alcohol =360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or had a positive alcohol breath test or could not abstain during the trial.
- •Subjects who smoked more than 5 cigarettes per day in the 6 months prior before screening or could not give up during the trial.
- •Subjects who have abnormal laboratory test: neutrophil count<1.5 x10^9/L,or white blood cell count<3.5 x10^9/L,or creatine kinase greater than the upper limit of normal at screening.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Effect on QTcF between baseline and post-dose treatment of FXS5626
Time Frame: 45 min before administration and 24 hours after administration
The Cmax geometric mean corresponds to the upper 90% bilateral confidence interval of ΔΔQTcF
To access the incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests [Safety and Tolerability] of single ascending oral dose of FXS5626 in healthy adults.
Time Frame: Approximately 1 week
The incidence and severity of adverse events (AEs) , serious AEs and abnormalities on laboratory tests
Secondary Outcomes
- Plasma concentration and pharmacokinetic parameters(10 min before administration and 48 hours after administration)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..Cutaneous Lupus ErythematosusSystemic Lupus ErythematosusNCT07408908Xiamen Amoytop Biotech Co., Ltd.48
Not yet recruiting
Phase 1
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia (AML)NCT07676006Grit Biotechnology36
Not yet recruiting
Phase 1
Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung DiseaseInterstitial Lung Disease (ILD)NCT07570836Shanghai Zhongshan Hospital24
Recruiting
Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult ParticipantsNCT07345364Jiangsu Simcere Pharmaceutical Co., Ltd.72
Not yet recruiting
Phase 1
A Phase I Study of PepGNP-ChikV in Healthy VolunteersChikungunyaChikungunya FeverNCT07394426Gylden Pharma Ltd40